Format
Sort by

Send to:

Choose Destination

Search results

Items: 4

1.

Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.

Grijsen ML, Wit FW, Jurriaans S, Kroon FP, Schippers EF, Koopmans P, Gras L, Lange JM, Prins JM; Primo-SHM Study Group.

PLoS One. 2014 Apr 3;9(4):e89639. doi: 10.1371/journal.pone.0089639. eCollection 2014.

2.

Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study.

Grijsen M, Koster G, van Vonderen M, van Kasteren M, Kootstra G, Steingrover R, de Wolf F, Prins J, Nieuwkerk P; Primo-SHM study group.

HIV Med. 2012 Nov;13(10):630-5. doi: 10.1111/j.1468-1293.2012.01020.x. Epub 2012 Apr 25.

3.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.

PLoS Med. 2012;9(3):e1001196. doi: 10.1371/journal.pmed.1001196. Epub 2012 Mar 27.

4.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, MirĂ³ JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group.

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk